RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Intellia Therapeutics Stock

Intellia Therapeutics Equity 2025

Intellia Therapeutics Equity

1.05 B USD

Ticker

NTLA

ISIN

US45826J1051

WKN

A2AG6H

In 2025, Intellia Therapeutics's equity was 1.05 B USD, a -15.01% increase from the 1.24 B USD equity in the previous year.

Intellia Therapeutics Aktienanalyse

What does Intellia Therapeutics do?

Intellia Therapeutics Inc is a leading biotechnology company specializing in the development of therapeutic solutions based on CRISPR/Cas9 technologies. It was founded in May 2014 and is headquartered in Cambridge, Massachusetts, USA. The company is listed on NASDAQ under the ticker symbol NTLA. Intellia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Intellia Therapeutics's Equity

Intellia Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Intellia Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Intellia Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Intellia Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Intellia Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Intellia Therapeutics stock

What is the equity of Intellia Therapeutics this year?

Intellia Therapeutics has equity of 1.05 B USD this year.

What was the equity of Intellia Therapeutics compared to the previous year?

The equity of Intellia Therapeutics has increased/decreased by -15.01% decreased compared to the previous year.

What impact does a high equity have on investors of Intellia Therapeutics?

A high equity is advantageous for investors of Intellia Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Intellia Therapeutics?

A low equity can be a risk for investors of Intellia Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Intellia Therapeutics affect the company?

An increase in equity of Intellia Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Intellia Therapeutics affect the company?

A reduction in equity of Intellia Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Intellia Therapeutics?

Some factors that can affect the equity of Intellia Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Intellia Therapeutics so important for investors?

The equity of Intellia Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Intellia Therapeutics take to change the equity?

To change equity, Intellia Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Intellia Therapeutics pay?

Over the past 12 months, Intellia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intellia Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Intellia Therapeutics?

The current dividend yield of Intellia Therapeutics is .

When does Intellia Therapeutics pay dividends?

Intellia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intellia Therapeutics?

Intellia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Intellia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intellia Therapeutics located?

Intellia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intellia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intellia Therapeutics from 2/16/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/16/2025.

When did Intellia Therapeutics pay the last dividend?

The last dividend was paid out on 2/16/2025.

What was the dividend of Intellia Therapeutics in the year 2024?

In the year 2024, Intellia Therapeutics distributed 0 USD as dividends.

In which currency does Intellia Therapeutics pay out the dividend?

The dividends of Intellia Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Intellia Therapeutics

Our stock analysis for Intellia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intellia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.